Search for a trial

An open label, multi-center roll-over study to assess long-term safety in patients who are ongoing or have completed a prior global Novartis or GSK sponsored Tafinlar (dabrafenib) and/or Mekinist (trametinib) study and are judged by the investigator to benefit from continued treatment

This study has been transitioned to CTIS with ID 2023-509318-13-00 check the CTIS register for the current data. This is an open-label, multi-center, roll-over study designed to provide continued access to subjects who have previously participated…

Phenotyping study of the CYP3A4 activity in patients with prostate cancer versus
male patients with other types of solid tumours with midazolam

The primary objective is comparison of the CYP3A4 activity in medically castrated patients with prostate cancer with the CYP3A4 activity of male patients with other types of solid tumours. To evaluate the CYP3A4 activity, the PK of the CYP3A4…

Self-management of persons with advanced cancer and their relatives (SMART): the Living with Cancer Programme

To evaluate the effectiveness of a peer-led, video-based self-management support programme for patients with advanced cancer and their relatives. The programme aims to improve the wellbeing of patients with advanced cancer and their relatives,…

Quality Assessment of New Liquid Biopsy Techniques

The main objective of this study is to perform a quality assessment on several new techniques, used in the laboratory of Translational Cancer Genomics and Proteomics

Validation of mutation analysis in circulating tumor DNA with a ddPCR assay as diagnostic and follow-up tool for patients with a KIT exon 11 mutated GIST: GALLOP-11

To establish the negative predictive value of the designed KIT exon 11 circulating tumor mutation assay in relation to CT-scans (and/or MRI scans).

A Phase 1, Open-label, Dose-escalation and Expansion Study of MEDI1191 Administered Intratumorally as Monotherapy and in Combination with Durvalumab in Subjects with Advanced Solid
Tumors.
Sub-study title: CD8+ Imaging Sub-study Protocol

Objectives (all are exploratory):• To measure and analyze 89Zr-Df-IAB22M2C uptake cluster of (CD8+ PET signal) at and between baseline and post-treatment in tumor lesions and reference normal tissues, including T-cell rich tissues, using PET imaging…

A Clinical Evaluation of the Aliya* System in Late-Stage Cancer (INCITE LS)

To evaluate the safety and clinical utility of PEF treatment of advanced stage or metastatic cancer following progression on immunotherapy

A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours (POTENTIA)

Primary Objective:To assess the safety and tolerability and determine the MTD and the RP2D of CB307 in patients with PSMA+ tumoursSecondary Objectives:• To characterise the serum PK of CB307• To characterise the immunogenic potential of CB307 and…

Real-world exploratory evaluation of the potential drug-drug interaction between anticancer small molecule inhibitors and direct oral anticoagulants in patients with solid tumours, and exploration of the role of therapeutic drug monitoring

Primary Objective: to explore the effect of SMIs on the pharmacokinetics of DOACs in patients with solid tumours who receive a DOAC and SMI concurrently. Secondary Objective(s): - To determine the percentage of patients with DOAC peak and trough…

A Phase 1, Multicenter, Open-Label Study of SQZ-AAC-HPV as
Monotherapy and in Combination with Immune Checkpoint
Inhibitors in HLA-A*02+ Patients with HPV16+ Recurrent, Locally
Advanced or Metastatic Solid Tumors

Primary ObjectivesPart 1 (Monotherapy Dose Escalation Phase):* To determine the recommended Phase 2 dose (RP2D) of SQZ AAC HPV monotherapy. * To characterize the safety and tolerability of SQZ AAC HPV administered as monotherapy. Part 2 (Combination…

Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas; a randomized phase II clinical trial

to compare the short-term toxicity of the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week Overall Treatment Time (OTT) to 14 x 3 Gy, once daily fractionation in a three-week OTT, with respect to the rate of postoperative…

Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of Tinostamustine, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients with Advanced Solid Tumors

The ability to fuse discrete small molecules with different types of pharmacologic activity has created remarkable opportunities in drug discovery and development. Bendamustine itself is a fusion molecule of the nitrogen mustard mechlorethamine and…

Test-retest validation of quantitative MRI

The primary objective is to determine the repeatability of quantitative MRI measures on either a diagnostic MRI system or MRL.

A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma

This study has been transitioned to CTIS with ID 2023-508318-41-00 check the CTIS register for the current data. Primary Objective:• To determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination…

A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS WITH A KRAS G12C MUTATION

This study has been transitioned to CTIS with ID 2023-506311-18-00 check the CTIS register for the current data. This Phase Ia/Ib study will evaluate the safety, pharmacokinetics, immunogenicity (as applicable for study biotherapeutics), preliminary…

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-
PNT2002 PSMA Therapy After Second-line Hormonal Treatment

This study has been transitioned to CTIS with ID 2024-515604-39-00 check the CTIS register for the current data. The purpose of this research study is to learn about the safety and effectiveness of 177Lu-PNT2002, an investigational agent being…

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

This study has been transitioned to CTIS with ID 2023-503905-12-00 check the CTIS register for the current data. The main objectives for this study are: - To assess the safety and tolerability of the combination of pembrolizumab and lenvatinib and…

Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1

This study has been transitioned to CTIS with ID 2024-514907-32-00 check the CTIS register for the current data. To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality…

Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiation in sarcopenic head and neck cancer patients.

This study has been transitioned to CTIS with ID 2024-514919-10-00 check the CTIS register for the current data. To investigate if the use of weekly low dose cisplatin increases compliance to the planned chemotherapy scheme in LA-HNSCC patients with…

The effectiveness of patient-tailored interdisciplinary Medical Specialist Cancer Rehabilitation compared with allied health care on quality of life in patients with complex adverse effects of cancer or the treatment.

The research objectives of this study are divided in a primary research objective and secondary research objectives.Primary:1. To study the effectiveness on the short and long term of patient-tailored interdisciplinary MSCR compared with AHC on the…